Skip to content
Dosage GuideResearch Reference

BDNF Mimetic Peptides Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for BDNF Mimetic Peptides. All information is for educational purposes only.

Quick Answer

No human clinical trials have established a standard dosage for BDNF mimetic peptides like LM22A-4. Preclinical studies in mice used oral doses of 50–500 mg/kg. Human equivalent doses would need careful Phase I studies. These are research compounds, not supplements, and are not available for human use.

→ BDNF Mimetic Peptides Benefits→ BDNF Mimetic Peptides Side Effects→ Full BDNF Mimetic Peptides Profile
Table of Contents

Standard Dosage Range

Research dosing range: Not established (preclinical research only)

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Neuroprotection in Alzheimer's Disease (animal models)

50-200 mg/kg1-2× daily
Duration

8-12 weeks

Based on mouse studies with LM22A-4. Oral gavage administration. Reduced tau phosphorylation and neuronal loss in transgenic models.

Antidepressant Effects (animal models)

100-300 mg/kg1× daily
Duration

2-4 weeks

Based on rodent studies. Oral administration. Showed rapid antidepressant-like effects in forced swim and tail suspension tests.

Traumatic Brain Injury Recovery (animal models)

200-500 mg/kg1× daily
Duration

4-8 weeks

Based on mouse TBI studies. Oral gavage. Promoted neuronal survival and functional recovery post-injury.

Timing & Frequency

Animal studies typically administer the dose in the morning. The half-life and optimal human dosing schedule are unknown.

Cycle Guidance

No human data exists to guide cycling. Animal studies used continuous administration for several weeks. Given the theoretical risk of oncogenesis with chronic TrkB activation, intermittent cycling might be a prudent precautionary approach pending human data.

Reconstitution Reference

Quick reference for reconstituting BDNF Mimetic Peptides. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizeN/A (typically supplied in powder form for research)
BAC Water VolumeN/A
Concentration & DrawN/A
StorageFollow manufacturer instructions. Usually refrigerated.
StabilityFollow manufacturer instructions.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the human equivalent dose for LM22A-4?
There is no established human equivalent dose. Animal studies used 50-500 mg/kg in mice. Human dose translation requires careful pharmacokinetic/pharmacodynamic modeling and Phase I safety studies, which have not been performed.
Are BDNF mimetic peptides legal to purchase?
LM22A-4 and other BDNF mimetics are available for research purposes only through chemical suppliers. They are not approved as drugs or supplements and are not legal for human consumption.
Can I take these peptides orally?
Preclinical studies have demonstrated oral bioavailability for LM22A-4. However, the absorption, distribution, metabolism, and excretion (ADME) profile in humans is unknown. Do not ingest without proper clinical trials.
How long do BDNF mimetic effects last?
The duration of effects depends on the specific compound and dosing regimen. No human data available. Animal studies showed sustained benefits with chronic administration.

References

  1. 1
    Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents(2010)PubMed ↗
  2. 2
    LM22A-4, a small-molecule TrkB agonist, reduces apoptosis and promotes recovery after traumatic brain injury(2015)PubMed ↗
  3. 3
    Orally active, brain-penetrating small-molecule TrkB agonists for the treatment of neurodegenerative diseases(2013)PubMed ↗

Last updated: 2026-02-19